ProQR Therapeutics (NASDAQ:PRQR) is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.
Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives. Its dual-platform approach—combining site-directed RNA editing with direct RNA therapies—underpins efforts to address a range of monogenic disorders affecting the eye, skin and other organ systems. By focusing on mRNA modulation rather than permanent DNA edits, ProQR seeks to deliver treatments that may offer reversibility and a favorable safety profile.
ProQR has advanced multiple programs into early- and mid-stage clinical trials in North America and Europe, collaborating with leading academic institutions and industry partners. Multidisciplinary teams in molecular biology, translational research, and clinical development drive the company’s efforts to demonstrate proof of concept and navigate regulatory pathways. Ongoing studies aim to establish dosing, safety and efficacy in patient populations with high unmet medical needs.
Led by CEO Daniel de Boer and supported by a management team with extensive expertise in biotechnology and ophthalmology, ProQR continues to refine its platforms and expand its pipeline. The company actively pursues strategic partnerships and funding opportunities to accelerate its mission of transforming lives through innovative RNA medicines for rare genetic disorders.
